Products and Services

Next Generation Sequencing
Sample Preparation

  • box1


    Library Preparation kits for Illumina® NGS Platforms

    Rapid DNA-seq Kits (Currently in Beta testing/Development – Consumer Beta Kits available late 2017, Product launch in early 2018)
    WGS –
    PCR free –

    Library Prep Kits (R&D – anticipated 2018)
    RNA seq –
    Bisulfite seq –
    ChIP seq  –

SeqOnce Image copy

     Single Tube
     Simple – Rapid – Workflow
     30-40 min Library

  SeqOnce Rapid DNA-seq kit features:

–   Input DNA: 500pg or greater  (R&D – lower input)
–   Single tube preparation procedure
–   Simplified sample preparation with minimal hands on time
–   Applied to fragmented ds or ssDNA
–   30 – 40 min preparation time  (R&D 12 – 15 min PCR free)


For testing or purchasing information email:

Service – NGS – Sample preparation as a service

Service – Nanoparticles – Custom Nanoparticles and Conjugates

Custom Nanoparticle and conjugate synthesis for a wide variety of research and industrial applications


NGS – Sample Prep Technology

SeqOnce has developed a novel sample preparation approach which is faster and equivalent in quality to other products.
This proprietary technology incorporates a unique set of enzymatic reactions, which reduces reaction steps and reagents.

– Single tube preparation
– Input DNA as low as 500 pg, (lower input in R&D)
– DNA or cDNA (strand specific) preparation can be done with or without PCR (testing)
– Preparation time: with PCR – 30-40 min,  PCR free – 12-15 min (in R&D)
– Reduces preparation associated sequencing error

Nanoparticle Technology

SeqOnce has the ability to precisely synthetically control structure and composition of single- and mixed-metal nanoparticles [MMNPs]. This is key to tailoring their activity for specific roles in biomedical applications and material sciences and is, therefore essential in programming and optimizing their application-specific function.

SeqOnce has a wide range of custom nanoparticle synthesis, as well as bio-conjugates. We can provide nanoparticles from Nobel Metals, Transition Metals, Metalloids, Alkali Metals and Rare Earth metals as well as their stable and radio-isotopes.

SeqOnce can provide sterile nanoparticle suspensions and their affinity-targeted conjugates

Research & Development

Next Generation Sequencing

Targeted Sequencing
Synthetic long read technologies


Targeted Delivery

NGS - Applications

Next Generation Sequencing (NGS) and Sample Preparation

Due to rapid progress and recent technological advances the cost of next generation sequencing has decreased dramatically over the past decade. However, the cost of sample preparation has not seen a concurrent cost reduction, with the result that sample preparation has been a limiting factor in the field. Fortunately, this is no longer the case and as a result of our revolutionary patented process we offer sample preparation (both DNA and RNA) at a fraction of the cost compared to other vendors. NGS applications include:

  • Whole-genome sequencing
  • Exome sequencing
  • Targeted sequencing
  • Total and mRNA sequencing
  • Methylation sequencing
  • ChIP-seq
  • Mitochondrial sequencing

DNA-seq (Whole Genome)

Whole-genome sequencing which allows for the entire genome of the organism to be determined enabling the identification of SNP's, indels and copy number variants. This information is necessary for further understanding the connection between mutations and different diseases. Mitochondrial sequencing is also commonly used to determine the mitochondrial genetic variation underlying disease, to measure heteroplasmy, to facilitate taxonomic identification, as well as for population genetics applications.


RNA-seq is a technique that utilizes next-generation sequencing to explore transcriptome profiling and gene expression by analyzing the presence and quantity of RNA. RNA seq allows for far more precise measurements than other current methods such as hybridization (e.g. microarrays) or Sanger sequencing. This method can be used to ascertain the abundance of total RNA, noncoding RNA as well as small RNA’s. RNA seq facilitates the ability to identify:

  • Splicing patterns (and other post-transcriptional modifications)
  • Gene expression profiles (as conditions and/or development changes
  • Start sites, 5’ and 3’ ends
  • Novel and/or rare transcripts

Targeted Sequencing

Targeted sequencing isolates specific regions of interest in the genome and allows for increased cost effectiveness as well as coverage depth. Common uses for this technique include SNP validation, characterization of splice variants and to allow for accurate sequencing across repeats.


Methyl-seq, or bisulfite sequencing, is a technique that can be utilized to determine DNA methylation patterns. DNA methylation is a mechanism that cells use to control gene expression and is thought to play a role in a number of cellular processes (e.g. genomic imprinting, chromosome stability and during embryonic development), and errors in methylation have been linked to diseases such as cancer, lupus, muscular dystrophy as well as a number of birth defects. The technique to determine these methylation patterns relies on the fact that DNA treated with sodium bisulfite will react differently depending on whether the cytosines are methylated or not, and these differences can be subsequently identified by sequencing.


ChIP-seq is a technique that combines Chromatin immunoprecipitation (ChIP) with next-generation sequencing in order to ascertain how gene expression is influenced by the interactions between DNA and its associated proteins. In this method the transcription factor, cofactor, replication-related factor, or other chromatin protein is enriched through immunoprecipitation (an antibody based technique) in conjunction with its associated DNA. The enriched DNA can then be identified by sequencing thereby enabling the binding site of the factor to be determined, as well as the genome wide identification of all the regulatory sites for the associated factor.

Exome Sequencing

Exome sequencing which sequences only the protein coding regions of the genome. This technique is very useful for the detection of genetic variation that is likely to cause disease without incurring the cost associated with sequencing the entire genome.

Nanoparticle Applications

– Flow Cytometry, UV-Visible, Infrared, Rahman and Mass Spectroscopy/Cytometry
– Proteomics and Genomics
– Targeted drug delivery: Customized Synthesis of Individual Stable Isotopes and Targeted Radioisotope Nanoparticles
– Magnetic Separation and Purification of Proteins, Nucleic Acids, Macromolecules, Whole Cells and Cell Fragments
– Imaging: Correlative Microscopy


About Us

SeqOnce Biosciences is a privately held company located in Pasadena, California. Our core competencies, including enzymology, nucleic acid chemistry, sample processing and manufacturing, have served as engines for innovation, development of intellectual property, and ongoing product development.

SeqOnce Biosciences was formed in 2014 by Joseph Dunham, Ph.D, a researcher at the University of Southern California and Chris Angermayer, a former portfolio manager and investment analyst. The founders are dedicated to building a team of individuals who are leaders in the industry, thereby enabling SeqOnce to become a preeminent player in the NGS sample preparation market. In 2016, Marcus Yaffee, Ph.D., a leading researcher in the area of nanoparticle synthesis joined SeqOnce to spearhead nanotechnology research and development. Marcus brings a wealth of knowledge of Nanotechnologies for use in the research and diagnostic markets. The marriage of chemistry and molecular biology is currently in research and development.


Management Team and Advisors

Chris Angermayer

Chris Angermayer

Chief Executive Officer – Co Founder

Chris’ experience includes many years as a trader, investment analyst and portfolio manager. Chris has experience with the evaluation of private equity and venture finance opportunities. Most recently he has been working with small companies on financial analysis and business development. He has experience with startup financial operations.

He holds a B.A. in political science from Loyola Marymount University (including study at Oxford University) and an M.B.A. in finance from the University of Southern California’s Marshall School of Business. He is a recipient of the Genetics and Genomics Certificate from Stanford University.

Jennifer Hannigan

Jennifer Hannigan

Executive Vice President - Strategic Planning and Operations

Jenn has served in a variety of executive roles in life science, healthcare and consulting organizations were she spearheaded start-ups, turn-arounds, transitions &  aggressive transformation and growth efforts. Jenn leverages her scientist-practitioner-strategy-operations background and CXO relationships in developing emerging companies & collaborative partnerships. She has co-conducted over 200 clinical trials and co-built $MM/$B practices. Jenn has served on a variety of boards and has been recognized for her “exemplary leadership & outstanding achievement in healthcare” by the Healthcare Businesswomen’s Association.

Jenn holds a BA in psychology, Arizona State University; MS.Ed in Behavioral Medicine, University of Miami; MPH from the University of Miami Leonard M. Miller School of Medicine and has been admitted to candidacy, (awaiting defense) Ph.D. in Interdisciplinary Medicine, University of Miami/University of Miami Leonard M. Miller School of Medicine.

Sergey Nuzhdin, Ph.D.

Sergey Nuzhdin, Ph.D.


Sergey holds a Master of Science (Biophysics: 1989), from Moscow State University (Moscow, Russia), a Ph.D. (Genetics; 1992) from the Institute of Molecular Genetics (Moscow, Russia). He completed his post doctoral work at North Carolina State University (1997).

Sergey is a professor of Biological Sciences at the Dornsife College of Arts and Letters at the University of Southern California. His research in genetics and genomics has yielded 112 publications in various journals including Nature, Current Biology and Science, among others.

Joseph Dunham, Ph.D.

Joseph Dunham, Ph.D.

Chief Science Officer – Co Founder

Having worked in academic research for over 15 years, Joseph has held multiple positions. Joseph has been involved with technology development for next generation sequencing and imaging diagnostics. He assisted in the development of RAD for RAD sequencing during his undergraduate studies.

He holds a B.S. in Biology from the University of Oregon and a Ph.D. in Molecular and Computational Biology at the University of Southern California. His doctoral work was supported by an EUREKA RO1 award of $1.2 million he co-wrote for stem cell heterogeneity population genomics during regeneration. He continued his dedication to interdisciplinary training and translational research and pursued a Postdoctoral Scholar position with Dr. Scott Fraser at the University of Southern California. His postdoctoral efforts to co-develop a single molecule signal amplification technology (MUSE) has resulted in patents and Dr. Fraser and team received the Chan Zuckerberg Initiative award for the application of MUSE for single molecule transcript neuronal imaging as a part of the Human Cell Atlas initiative.

Marcus Yaffee, Ph.D.

Marcus Yaffee, Ph.D.

Sr. Research Scientist - Nanotechnology

Marcus Yaffee studied Chemistry at the University of New Mexico, and the University of Cambridge. He was awarded his Ph.D. from the Swiss Federal Institute of Technology, Zurich and a professional MPH (Toxicology/EHS) at UC Berkeley (2006). He was Senior Scientist, Nuclear Medicine, University Hospital Bern, Switzerland (2012), and previously was a research scientist in the group of Prof. Scott Fraser at the USC Translational Imaging Center.

Dr. Yaffee’s professional skillsets include Synthetic Chemistry, Cell biology, Biophysics, Immunology and Toxicology as well as their clinical application. Previously he was a senior scientist at Molecular Probes (Thermo).

Scott E. Fraser, Ph.D.

Scott E. Fraser, Ph.D.


Scott E. Fraser Ph.D., has a long-standing commitment to quantitative biology, applying the tools of chemistry, engineering and physics to problems in biology and medicine. His personal research centers on imaging and molecular analysis of intact biological systems, with an emphasis on early development, organogenesis and medical diagnostics.

Fraser left Caltech in 2012 to become a Provost Professor at the University of Southern California’s Dornsife College of Letters, Arts and Sciences, Children’s Hospital Los Angeles, the Keck School of Medicine of USC and USC Viterbi School of Engineering. As USC’s Elizabeth Garrett Chair of Convergent Bioscience, he fosters translation and builds new opportunities multidisciplinary science and engineering. He has published more than 200 peer-reviewed scientific papers and has served as an editor or board member for a half dozen journals. He has received 63 U.S. patents for inventions in fields ranging from imaging technologies to molecular sensors and medical diagnostics.

Fraser has helped interface industrial with academia, having served as a Science Advisory Board or Board of Director member for companies ranging from Amersham and GE to Zeiss. He has actively fostered translation through licensing and co-founding companies such as Clinical Micro Sensors and Varocto. Fraser is a Fellow of the European Academy of Science, the AAAS and the American Academy of Arts and Science and the National Academy of Inventors.

Strategic Partners and Affiliations

News & Events

Sep 2017

Jennifer Hannigan to join SeqOnce as the Executive Vice President of Strategic Planning and Operations

Aug 2017

SeqOnce to partner with Washington State University

Jul 2017

SeqOnce Biosciences highlighted in Genomeweb article:

Mar 2017

New Rapid DNA-seq kits available for testing – contact SeqOnce for more information

Dec 2016

SeqOnce and Episona Inc. to collaborate on strategic initiatives

Nov 2016

Custom nanoparticle products available for testing, contact SeqOnce for more information

Nov 2016

SeqOnce partners with Salk Institute for product testing

Oct 2016

SeqOnce partners with Michigan St. University for consulting services and product testing

Aug 2016

Dr. Scott E. Fraser to join SeqOnce as a scientific advisor

Feb 2016

Dr. Marcus Yaffee joins SeqOnce to spearhead nanotechnology research and development

Oct 2015

SeqOnce partners with the University of Bologna – Italy researchers for consulting services

Sep 2015

SeqOnce partners with Iowa St. University researcher for consulting services

May 2015

SeqOnce partners with The Los Angeles County Museum of Natural History for consulting services

Mar 2015

SeqOnce partners with Harvey Mudd College researcher for consulting services

Feb 2015

SeqOnce licenses the undivided interest in sample preparation technology from the University of Southern California

Feb 2014

SeqOnce formed to fund research and development for Next Generation Sequencing sample preparation and related applications

Contact Us

Get in Touch with Us

SeqOnce E-Mail List Privacy Policy
Our email list is used to keep you and others informed about SeqOnce Biosciences Inc. products and company updates.
We do not share or sell your information to any third parties. We may use data from the list in the form of aggregate statistics, which do not identify you, ie: for tracking Web usage only.
If you have any question or concerns, please contact us at

Copyright © 2015 SeqOnce. All rights reserved.